Competing interests
R01HL137734 R01HL137794 R01HL141434, McManus, MyoKardia
HEART
Dr. Atlas receives sponsored research support from Bristol Myers Squibb / Pfizer and American Heart Association 18SFRN34250007. He has consulted for Bristol Myers Squibb/Pfizer and Fitbit. Dr. Ashburner is supported by NIH grant K01HL148506, American Heart Association 18SFRN34250007, and has received sponsored research support from Bristol Myers Squibb / Pfizer. Dr. McManus is supported by NIH grants R01HL137734 R01HL137794 R01HL141434 R01HL136660 R21AG060529 U54HL143541 U01HL146382 and receives sponsored research support from Apple, Bristol Myers Squibb / Pfizer, Boehringer Ingelheim, Flexcon, and has consulted for Bristol Myers Squibb / Pfizer, Heart Rhythm Society, Flexcon, and Avandia (Boston Biomedical) Associates. Dr. Ellinor is supported by grants from the National Institutes of Health (1RO1HL092577), by a grant from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and by a grant from the European Union (MAESTRIA 965286). Dr. Ellinor receives sponsored research support from Bayer AG and IBM Research; he has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. Dr. Lubitz is a full-time employee of Novartis as of July 18, 2022. Prior to his employment at Novartis and during this work he was supported by NIH grants R01HL139731, R01HL157635 and American Heart Association 18SFRN34250007. Dr. Lubitz previously received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier, and IBM, and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences, and Invitae.